Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.

BACKGROUND The use of adjuvant chemotherapy in early breast carcinoma is controversial, with most advocating its use in high-risk patients as defined by specific clinicopathologic parameters. Both bcl-2 and p53, which play a role in determining tumor growth by their effects on apoptosis and cell proliferation respectively, may serve to delineate this subset more accurately. The purpose of this study was to determine the prognostic value of bcl-2, Bax, and mutant p53 in stage I breast cancer. STUDY DESIGN A total of 75 patients with stage Ic breast carcinoma diagnosed from 1989 to 1992 were identified retrospectively and clinicopathologic parameters such as age, tumor size, estrogen receptor (ER) and progesterone receptor (PR) status, disease-free survival and overall survival obtained. Paraffin-embedded formalin-fixed tissues were immunostained with bcl-2, Bax and p53 monoclonal antibodies using a standard avidin biotin peroxidase reaction. Stained slides were evaluated by two independent pathologists for staining intensity and percentage of cells staining positively. Cox regression was used for multivariate survival analysis using the clinicopathologic parameters and molecular markers. Chi-square tests were used for frequency tables. RESULTS Mean patient age was 58 years (range 29 to 79 years) with a median followup of 80 months from time of diagnosis. The most common histopathology was infiltrating ductal carcinoma. Neither bcl-2 nor Bax expression was associated statistically with disease-free or overall survival. Expression of mutant p53 was associated with a significant decrease in both 5-year disease-free survival (70% versus 98%, p </= 0.01 in multivariate analysis) and 5-year overall survival (74% versus 100%, p = 0.03). Expression of bcl-2 was associated with hormone receptor expression and tumor diploid status. Of tumors expressing bcl-2, 36 of 49 (73%) were ER+ (p = 0.017, versus tumors not expressing bcl-2, 6 of 15 [40%]), 22 of 49 (45%) PR+ (p = 0.027 versus tumors not expressing bcl-2, 2 of 15 [13%]) and 28 of 44 (64%) diploid (p = 0.004 versus tumors not expressing bcl-2, 1 of 9 [11%]). CONCLUSIONS These results indicate that bcl-2 expression is significantly associated with hormonal receptor status and that p53 is a significant prognostic marker for survival in early breast cancer.

[1]  M. Mathieu,et al.  c‐myc, p53 and bcl‐2, apoptosis‐related genes in infiltrating breast carcinomas: Evidence of a link between bcl‐2 protein over‐expression and a lower risk of metastasis and death in operable patients , 1999, International journal of cancer.

[2]  A. Hartmann,et al.  The molecular epidemiology of p53 gene mutations in human breast cancer. , 1997, Trends in genetics : TIG.

[3]  G. Jacobsen,et al.  An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. , 1995, Human pathology.

[4]  S. Ciatto,et al.  Lack of Prognostic Value of p53 Protein Expression in Node-Negative Breast Cancer , 1997, Tumori.

[5]  S. Korsmeyer,et al.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P Sismondi,et al.  Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients , 1998, International journal of cancer.

[7]  S. Syrjänen,et al.  p53 protein expression in breast cancer as related to histopathological characteristics and prognosis , 1993, International journal of cancer.

[8]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[9]  R. González-Sarmiento,et al.  Analysis of bcl‐2 in sporadic breast carcinoma , 1997 .

[10]  L. Leung,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1999.0706 Paradoxical regulation of Bcl-2 family proteins by , 2022 .

[11]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[12]  M. Inganäs,et al.  Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. , 1998, Cancer research.

[13]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[14]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[15]  D. Hockenbery,et al.  Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. , 1998, The Journal of surgical research.

[16]  S. Fox,et al.  Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. , 1996, Human pathology.

[17]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[18]  A. Lazaris,et al.  PROGNOSTIC SIGNIFICANCE OF THE CO‐EXPRESSION OF p53 AND c‐erbB‐2 PROTEINS IN BREAST CANCER , 1996, The Journal of pathology.

[19]  R. Elledge,et al.  p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. , 1994, Cancer research.

[20]  B. Iacopetta,et al.  Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[22]  M. J. van de Vijver,et al.  Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. , 1996, British Journal of Cancer.

[23]  John Calvin Reed,et al.  Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity , 1995, Cell.

[24]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[25]  Yi-Song Wang,et al.  Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. , 1993, Oncogene.

[26]  G. Palumbo,et al.  17β-Estradiol Inhibits Apoptosis in MCF-7 Cells, Inducing bcl-2 Expression via Two Estrogen-Responsive Elements Present in the Coding Sequence , 2000, Molecular and Cellular Biology.

[27]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[28]  S. Korsmeyer.  Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.

[29]  M. Gentile,et al.  p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. , 1999, European journal of cancer.

[30]  U. Göhring,et al.  P53 protein in 204 patients with primary breast carcinoma — immunohistochemical detection and clinical value as a prognostic factor , 2004, Archives of Gynecology and Obstetrics.

[31]  Meterissian Sh.  Apoptosis: its role in the progression of and chemotherapy for carcinoma. , 1997 .

[32]  U. Veronesi,et al.  p53 as an independent prognostic marker in lymph node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.

[33]  R. Seruca,et al.  P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach. , 1998, Pathology, research and practice.